About 773 results

ALLMedicine™ Agammaglobulinemia Center

Research & Reviews  262 results

Meningoencephalitis in primary antibody deficiency: Our experience from northwest India.
Journal of Neuroimmunology; Jindal AK, Chaudhary H et. al.

Aug 29th, 2022 - Patients with primary antibody deficiency (PAD) are predisposed to develop meningoencephalitis, often considered to be enteroviral. However, there is a paucity of literature on this subject, and there are no studies from developing countries. We a...

COVID-19-related health outcomes in people with primary immunodeficiency: A systematic ...
Clinical Immunology (Orlando, Fla.); Drzymalla E, Green RF et. al.

Aug 17th, 2022 - A better understanding of COVID-19 in people with primary immunodeficiency (PI), rare inherited defects in the immune system, is important for protecting this population, especially as population-wide approaches to mitigation change. COVID-19 outc...

Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-s...
Immunity Gao Y, Cai C et. al.

Aug 13th, 2022 - Many immunocompromised patients mount suboptimal humoral immunity after SARS-CoV-2 mRNA vaccination. Here, we assessed the single-cell profile of SARS-CoV-2-specific T cells post-mRNA vaccination in healthy individuals and patients with various fo...

Response to mRNA COVID-19 vaccination in three XLA patients.
Vaccine Squire JD, Joshi AY

Aug 8th, 2022 - X-linked agammaglobulinemia (XLA) is an inborn error of immunity characterized by insufficient production of immunoglobulins and lack of measurable antibody response to vaccines. The rise of novel infections limits the protective effect of immunog...

Algerian Registry for Inborn Errors of Immunity in Children: Report of 887 Children (19...
Journal of Clinical Immunology; Yagoubi A, Tahiat A et. al.

Jul 16th, 2022 - Inborn errors of immunity (IEI) represent a heterogeneous large group of genetic disorders characterized by susceptibility of affected individuals to recurrent infections, autoimmune/inflammatory diseases, allergy, and malignancy. We aimed to repo...

see more →

Drugs  23 results see all →

Clinicaltrials.gov  6 results

COVID-19 Vaccine Responses in PIDD Subjects

Apr 11th, 2022 - Individuals with primary and secondary antibody immunodeficiency are at higher risk for severe COVID-19 disease. Humoral immunity is thought to be the predominant protection against COVID-19, however mRNA vaccines have been shown to elicit both an...

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

Aug 24th, 2021 - The purpose of this study is to determine the pharmacokinetics, efficacy and safety of Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution in subjects with primary immunodeficiency (PID) manifesting as hypo- or agammaglo...

Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia

Apr 8th, 2021 - PRIMARY OBJECTIVES: I. To estimate the biologic target activity of dasatinib in CLL patients found to have pre-treatment in vitro dasatinib cytotoxicity (as defined by a >= 50% decrease in absolute lymphocyte count and/or bone marrow CLL count and...

Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency

Aug 24th, 2020 - The purpose of this study is to assess the safety/tolerability and efficacy of using ustekinumab in subjects with common variable immunodeficiency CVID or selective IgG subclass deficiency (functional agammaglobulinemia) who have associated sympto...

Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older

May 31st, 2018 - Common variable immune deficiency (CVID), specific antibody deficiency (SAD), and X-linked agammaglobulinemia (XLA) are among the most common primary antibody deficiencies in which the mainstay of treatment is gammaglobulin replacement. The use of...

see more →

News  17 results

Byrd Discusses Optimizing Ibrutinib and Idelalisib in CLL

Dec 20th, 2020 - John C. Byrd, MD In a presentation at the inaugural ASH Meeting on Hematologic Malignancies, John C. Byrd, MD, discussed what his clinical experience has revealed about the optimal use of ibrutinib (Imbruvica) and idelalisib (Zydelig) in chronic ...

Ibrutinib Represents "Transformative" Approach in CLL Treatment

Dec 5th, 2020 - Jennifer R. Brown, MD, PhD Jennifer R. Brown, MD, PhD, and John Byrd, MD, leading researchers in the emerging field of Bruton tyrosine kinase (BTK) inhibition in chronic lymphocytic leukemia (CLL) and other B-cell malignancies, discussed key ques...

BTK Inhibitor Success Puts Focus on Resistance Mechanisms

Dec 5th, 2020 - Krithika Subramanian, PhD Less than 5 years after Bruton tyrosine kinase (BTK) inhibition was introduced in hematologic malignancies, the need for strategies to address primary and secondary mechanisms of resistance has emerged. The robust poten...

COVID-19 Outcomes Vary Widely in Patients With Primary Immunodeficiencies

Oct 20th, 2020 - NEW YORK (Reuters Health) - Clinical outcomes of COVID-19 in patients with primary immunodeficiency diseases range from mild illness to death, according to a small case series. "We were first surprised that we had only a few cases considering how ...

Dyspnea and Night Sweats in a 46-Year-Old Man

Jan 15th, 2020 - Which of the following is the most likely diagnosis? Your Peers Chose: Bruton agammaglobulinemia 0% Thymoma 0% Pheochromocytoma 0% Teratoma 0% Discussion The patient in this case was eventually diagnosed with thymoma. Symptoms from a thymoma or th...

see more →

Patient Education  1 results see all →